Rapid Micro Biosystems
Rapid Micro Biosystems' revenue rose 19.7% to $34 million in fiscal 2025. Its operating margin was −141.1%, up from −178.0% a year earlier. Free cash flow was −$32 million. The diluted share count rose 2.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Rapid Micro Biosystems lost money in fiscal 2025: a net loss of $47 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 194 | 109 | 92 | 51 | 38 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 19 |
| Net debt (negative means net cash) | −194 | −108 | −92 | −50 | −19 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.6x |
| Interest coverage | −17.8x | −1,505.2x | −1,488.5x | −1,248.0x | −43.5x |
| Current ratio | 12.0x | 7.3x | 6.3x | 4.6x | 3.3x |
| Quick ratio | 11.1x | 6.2x | 5.3x | 3.5x | 2.4x |
Cash flow
Projections
Project Rapid Micro Biosystems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Rapid Micro Biosystems shares on the open market, and 5 insiders sold $1.1 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | John J. Addington WilsonChief Operating Officer | Sold | 9,603 | $4.32 | $41,485 | Form 4 |
| Mar 11, 2026 | Sean M WirtjesChief Financial Officer | Sold | 7,480 | $4.32 | $32,314 | Form 4 |
| Mar 10, 2026 | Robert G. Spignesi Jr.President and CEO, Director | Sold | 17,922 | $4.11 | $73,659 | Form 4 |
| Feb 20, 2026 | Sean M WirtjesChief Financial Officer | Sold | 17,254 | $3.92 | $67,636 | Form 4 |
| Feb 20, 2026 | John J. Addington WilsonChief Operating Officer | Sold | 5,403 | $3.92 | $21,180 | Form 4 |
| Feb 19, 2026 | Robert G. Spignesi Jr.President and CEO, Director | Sold | 38,327 | $3.89 | $149,092 | Form 4 |
| Feb 9, 2026 | Robert G. Spignesi Jr.President and CEO, Director | Sold | 12,840 | $3.78 | $48,535 | Form 4 |
| Feb 9, 2026 | Sean M WirtjesChief Financial Officer | Sold | 6,027 | $3.78 | $22,782 | Form 4 |
| Feb 9, 2026 | John J. Addington WilsonChief Operating Officer | Sold | 4,610 | $3.78 | $17,426 | Form 4 |
| Feb 4, 2026 | Longitude Venture Partners II L.P.10% owner | Sold | 49,000 | $3.88 | $190,120 | Form 4 |
| Feb 3, 2026 | Longitude Prime Partners LLC10% owner | Sold | 27,500 | $4.24 | $116,600 | Form 4 |
| Feb 2, 2026 | Longitude Prime Partners LLC10% owner | Sold | 27,500 | $4.25 | $116,875 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 2 of 8 |
| Rule of 40 | −176.9% | −137.7% | −75.3% |
| Altman Z'' | −2.88 | −11.50 | −22.43 |
| Accruals ratio | −4.4% | −2.3% | −18.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 8 | 2 of 8 | 2 of 8 |
Compare
Put Rapid Micro Biosystems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rapid Micro Biosystems | FY25 | 19.7% | −141.1% | −95.0% | −192.8% | — | 2 | |
| MaxCyte | FY25 | −14.5% | −157.1% | −109.5% | — | — | — | Compare |
| Bionano Genomics | FY25 | −7.4% | −117.0% | −57.3% | −89.9% | — | 5 | Compare |
| Alpha Teknova | FY25 | 7.3% | −41.9% | −24.2% | −22.0% | — | 5 | Compare |
| Precipio | FY25 | 29.8% | −5.0% | 1.5% | −7.8% | −37.4x | 7 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 16 | 23 | 17 | 22 | 28 | 34 |
| Revenue growth | — | 44.5% | −26.2% | 31.4% | 24.6% | 19.7% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 6 | 10 | 13 | 13 | 15 | 14 |
| Operating income | −30 | −47 | −63 | −57 | −50 | −47 |
| Net income | −37 | −74 | −61 | −52 | −47 | −47 |
| Diluted EPS (US$) | −126.11 | −3.94 | −1.43 | −1.22 | −1.08 | −1.05 |
| Diluted shares (millions) | 0 | 20 | 42 | 43 | 44 | 45 |
| Cash flow | ||||||
| Cash from operations | −31 | −55 | −58 | −45 | −44 | −31 |
| Capital expenditure | 1 | 3 | 7 | 2 | 1 | 1 |
| Free cash flow | −32 | −58 | −65 | −47 | −46 | −32 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 4 | 5 | 4 | 4 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 45 | 194 | 109 | 92 | 51 | 38 |
| Debt incl. finance leases | 25 | 0 | 0 | 0 | 0 | 19 |
| Total assets | 70 | 241 | 191 | 144 | 98 | 75 |
| Total liabilities | 45 | 20 | 26 | 26 | 23 | 42 |
| Shareholders' equity | −127 | 221 | 164 | 118 | 75 | 33 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −190.0% | −203.3% | −369.0% | −251.2% | −178.0% | −141.1% |
| Net margin | −230.6% | −316.5% | −354.9% | −233.0% | −167.2% | −140.3% |
| Free cash flow margin | −197.1% | −250.4% | −381.1% | −208.4% | −162.3% | −95.0% |
| Rule of 40 (growth + FCF margin) | — | −205.9% | −407.3% | −176.9% | −137.7% | −75.3% |
| Return on capital | — | — | −119.8% | −108.8% | −154.4% | −192.8% |
| Return on equity | — | −156.5% | −31.6% | −37.2% | −48.5% | −86.8% |
| Return on assets | — | −47.3% | −28.2% | −31.4% | −38.8% | −54.5% |
| Net debt to EBITDA | — | — | — | — | — | — |